Benzinga | Jun 9, 2021 09:22AM EDT

DURECT Will Present Added Clinical Data From DUR-928 Studies In NASH, In Hepatic Impairment At Upcoming Int'l. Live Conference

DURECT Corporation (NASDAQ:DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL) to be held virtually June 23-26, 2021.

The first poster will discuss additional efficacy signals from a Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients. Previously reported data showed that DUR-928 was well tolerated at all three doses evaluated, 50mg QD, 150mg QD, and 300mg BID (600mg/day) with overall improvement from baseline observed in liver enzymes, serum lipid profiles, liver fat by imaging, and biomarkers of liver health. The poster will feature additional efficacy signal data including liver stiffness by transient elastography (TE) and magnetic resonance elastography (MRE), liver fibrosis marker, pro-C3, and ELF scores, as well as insulin resistance (HOMA-IR).

A second poster will provide data from a Phase 1 study assessing the safety, tolerability, pharmacokinetics (PK) of DUR-928 in subjects with moderate (Child-Pugh B scores) and severe (Child-Pugh C scores) hepatic impairment (HI), who received a single oral dose of 200mg DUR-928.

Poster Presentation Details:

Title: Efficacy Signals of 4-Week Oral DUR-928 in NASH Subjects

Poster #: 1198

Presenter: Eric Lawitz, M.D., Vice President, Scientific and Research Development, Texas Liver Institute

Date/Time: June 24-26, 2021

Poster Presentation Details:

Title: Safety and pharmacokinetics of DUR-928 in hepatic function impaired subjects

Session: 668

Presenter: Jaymin Shah, Ph.D., Executive Director, Clinical Pharmacology and Pharmacokinetics at DURECT

Date/Time: June 24-26, 2021

Copies of the posters will be available on DURECT's corporate website here at the conclusion of the conference.